Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

Yun Qiu, Lakshmeswari Ravi, Hsing Jien Kung

Research output: Contribution to journalArticle

258 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL- 6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalNature
Volume393
Issue number6680
DOIs
Publication statusPublished - May 7 1998
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells'. Together they form a unique fingerprint.

  • Cite this